Alternative Data for Verrica Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 6 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,300 | Sign up | Sign up | Sign up |
| X Mentions | 4 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc., a dermatological therapy company, develops and markets treatments for people with skin conditions in the United States. The company is headquartered in West Chester, Pennsylvania.
| Price | $6.11 |
| Target Price | Sign up |
| Volume | 236,846 |
| Market Cap | $98M |
| Year Range | $3.28 - $9.1 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Verrica Pharmaceuticals Q4 Earnings Call HighlightsMarch 11 - Yahoo Entertainment |
|
Pharmaceutical and Biotechnology Royalty Rates Agreements Report and Directory 2026: Insights Into 1,567 Licensing Transactions by Company A-Z, Therapeutic Area, Technology, Headline ValueMarch 12 - GlobeNewswire |
|
 |
12 Health Care Stocks Moving In Wednesday's Pre-Market SessionMarch 10 - Benzinga |
 |
Earnings Scheduled For March 11, 2026March 10 - Benzinga |
Verrica Pharma Announces Launch Of YCANTH In Japan By Its Partner, Torii Pharma, For Treatment Of Molluscum ContagiosumFebruary 8 - Benzinga |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 14M | 1.1M | 13M | -270,000 | 2M | 0.130 |
| Q2 '25 | 13M | 340,000 | 12M | 200,000 | 2.5M | 0.020 |
| Q1 '25 | 3.4M | 420,000 | 3M | -9.7M | -7.3M | -0.100 |
| Q4 '24 | 340,000 | 630,000 | -280,000 | -16M | -14M | -0.201 |
| Q3 '24 | -1.8M | 440,000 | -2.2M | -23M | -20M | -0.490 |
Insider Transactions View All
| Kirby John J. filed to buy 884 shares at $0. November 25 '25 |
| Rosenberg Noah L. filed to buy 589 shares at $0. November 25 '25 |
| Kirby John J. filed to buy 8,962 shares at $4.2. November 25 '25 |
| Rosenberg Noah L. filed to buy 2,357 shares at $4.2. November 25 '25 |
| Zawitz David filed to buy 2,500 shares at $0. November 25 '25 |
Similar companies
Read more about Verrica Pharmaceuticals (VRCA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x mentions, news mentions & customer reviews.
FAQ - Verrica Pharmaceuticals
The Market Cap of Verrica Pharmaceuticals is $98M.
Currently, the price of one share of Verrica Pharmaceuticals stock is $6.11.
The VRCA stock price chart above provides a comprehensive visual representation of Verrica Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Verrica Pharmaceuticals shares. Our platform offers an up-to-date VRCA stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Verrica Pharmaceuticals (VRCA) does not offer dividends to its shareholders. Investors interested in Verrica Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Verrica Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
